APL evolution in children during follow-up with at least 1 dosage before and after 6 months
| Non-persistent APL | Persistent APL | De novo APL | |
|---|---|---|---|
| Lupus anticoagulant (n=24) | 1 (4%) | 1 (4%) | 1 (4%) |
| Anticardiolipin IgG (n=54) | 9 (17%) | 5 (9%) | 5 (9%) |
| Anticardiolipin IgM (n=53) | – | – | 1 (2%) |
| Anti-β2GPI IgG (n=49) | 9 (18%) | 4 (8%) | 8 (16%) |
| Anti-β2GPI IgM (n=48) | 1 (2%) | – | 1 (2%) |
This table represents APL in children who have at least two APL determinations before and after 6 months in order to discriminate the passive transplacental transfer from APL synthesis de novo, as well as to represent the persistent APL.
Anti-β2GPI; anti-β2 glycoprotein-I antibodies; APL, antiphospholipid antibodies.